Compare State Street SPDR Bloomberg High Yield Bond ETF (JNK) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
State Street SPDR Bloomberg High Yield Bond ETF vs Revvity Inc — how do they compare? State Street SPDR Bloomberg High Yield Bond ETF trades at $95.74, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none, and Revvity Inc is trading nearer its 52-week high, State Street SPDR Bloomberg High Yield Bond ETF nearer its low. Which is the better fit depends on your goals.
| JNK | RVTY | |
|---|---|---|
Sector | Fixed Income | Technology |
52-Week High | $98.19 | $117.75 |
52-Week Low | $94.66 | $82.26 |
Market Cap | — | $12.33B |
Enterprise Value | — | $14.82B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JNK trades at $95.95, down 0.03% on the day, with a bearish technical signal from moving averages and neutral oscillators. The ETF maintains consistent dividend payments, with recent payouts of $0.52-$0.53. News highlights strong inflows into bond ETFs amid rising yields and Federal Reserve uncertainty, though some analysts caution on high-yield exposure.
Outlook is cautious due to bearish technicals and mixed sentiment; opportunities exist for income-seeking investors via dividends, but risks include potential Fed rate hikes and inflation pressures that could pressure high-yield bonds. Investor focus remains on macroeconomic cues.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About State Street SPDR Bloomberg High Yield Bond ETF
JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
